Introduction {#s1}
============

Osteoporosis is a disease that is clinically characterized by an increased risk for fracture due to reduced bone mineral density (BMD) and deterioration of bone quality ([@B29]). Osteoporotic fractures represent a major public health problem. Approximately 2 million osteoporotic fractures occur per year in the United States, incurring 17 billion US dollars in direct costs annually, and the burden is estimated to increase by 50% by 2025 ([@B7]). BMD has a high heritability (50%-85%) as shown in twin and family studies ([@B3]). Over the past 10 years, numerous genome-wide association studies (GWAS) have identified over 500 genetic loci associated with BMD and other osteoporosis (OP)-related traits ([@B7]; [@B19]; [@B32]; [@B68]; [@B2]; [@B54]). Although GWAS have been successful in identifying genetic loci for BMD, translating the genetic association findings into knowledge of the underlying biological mechanisms of bone biology and OP remains challenging, primarily due to the fact that most associations are from noncoding variation, the lack of bone-specific-omics resources, and the difficulties in establishing causality between variants, genes, and traits.

DNA methylation is an epigenetic regulation mechanism that plays a key role in many biological processes and disease susceptibility ([@B23]; [@B22]). DNA methylation also affects the differentiation and activities of bone cells ([@B46]) and contributes to the pathogenesis of OP ([@B74]). Epigenome-wide association studies (EWAS) have been applied to investigate the association between DNA methylation and BMD. The largest EWAS of BMD in bone specimens was performed in 84 postmenopausal women and identified 63 differentially methylated CpGs (DMCs) between healthy and osteoporotic women at a 10% false discovery rate after limiting the association analyses to CpG sites in the top 100 genes whose bone transcripts were previously associated with BMD ([@B64]). Due to the difficulties inherent in acquiring bone samples from human subjects, some recent EWAS used whole blood DNA as a proxy to assess the association. The largest EWAS for BMD in whole blood assessed DNA methylation at over 450,000 CpG sites with 5,515 subjects across five cohorts but failed to identify strong consistent association signal at any of the tested CpG sites ([@B53]). The finding of no significant associations was further substantiated by another independent EWAS of BMD comparing the whole blood DNA methylation of 32 primary OP patients with 16 controls ([@B21]), suggesting that the DNA methylation profile in whole blood may not accurately reflect the epigenomic status of bone cells. Moreover, although EWAS have extensively investigated the associations of DNA methylation and BMD, they were not able to elucidate the role of DNA methylation along the etiology pathway of the genetic variants to OP.

Recent studies suggest that DNA methylation modification could reside along the causal pathway between genetic variation and disease, either as the mediating factor contributing to the trait ([@B65]) or as a consequence of the trait ([@B77]). Identifying the role of epigenetic markers for disease risk along the causal pathway could be valuable in understanding the pathogenic mechanisms of OP. Mendelian randomization (MR) is a statistical method for dealing with this problem. It uses genetic variants robustly associated with modifiable exposures as instrumental variables to infer the causal relationship between the exposure and outcome variable ([@B12]; [@B13]). Generally, the observed association between a risk factor and an outcome trait can be explained in four kinds of causal pathways: causality, linkage, horizontal pleiotropy and reverse causality ([**Figure 1**](#f1){ref-type="fig"}). Using an MR framework, we can investigate whether DNA methylation resides along the causal pathway to disease ([@B63]). Such an effect is sometimes referred to as "mediation," as DNA methylation is mediating the effects from genetic variants to phenotype along the same biological pathway. Like other risk factors, DNA methylation is also vulnerable to confounding and reverse causality ([@B63]), but some recently developed methods can help to mitigate these problems. A bidirectional MR framework can distinguish causality from reverse causality ([**Figures 1D**](#f1){ref-type="fig"} and [**2**](#f2){ref-type="fig"}) ([@B76]), a fine-mapping and colocalization framework can identify whether the causal variants are in linkage ([**Figures 1D**](#f1){ref-type="fig"} and [**2**](#f2){ref-type="fig"}), and using multiple correlated instrumental variables (IVs) can distinguish causality from horizontal pleiotropy ([**Figures 1C**](#f1){ref-type="fig"} and [**2**](#f2){ref-type="fig"}) ([@B10]; [@B85]).

![Four possible models for an observed association between a trait and genetic variants through DNA methylation. **(A)** The genetic variant has an effect on the phenotype, mediated through DNA methylation. **(B)** The genetic variant that influences DNA methylation and the variant that influences the associated trait are in LD with each other. **(C)** The genetic variant influences both DNA methylation and phenotype by two independent biological pathways. **(D)** The genetic variant has an effect on the phenotype which then has a downstream effect on DNA methylation at this locus.](fgene-11-00060-g001){#f1}

![The analytical framework to evaluate the possible models for observed associations between a trait and genetic variants through DNA methylation. The causal relationship between DNA methylation and the trait is established by 2-sample Mendelian randomization (2SMR) with Egger regression to evaluate the horizontal pleiotropy effect. The causal mQTL is identified by fine mapping. The possibility of linkage model is declined by HEIDI test.](fgene-11-00060-g002){#f2}

In this study, we built a comprehensive MR framework to evaluate the mediation effect of DNA methylation for genetic influences on traits and applied our framework to discover the genetic causal pathways of OP ([**Figure 2**](#f2){ref-type="fig"}). In our analysis, we first identified the DMCs and methylation quantitative loci (mQTLs) in peripheral blood monocytes (PBMs) from 118 Caucasian women with divergent BMD values and then implemented the MR framework to infer the causal pathways mediated by DMCs. PBMs can serve as circulating precursors of osteoclasts, the bone-resorbing cells ([@B80]), and produce various cytokines that have profound effects on osteoclast differentiation, activation, and apoptosis ([@B82]). Due to the close biological relevance of PBM and bone metabolism, it has been widely utilized as a working cell model for studying the pathogenesis of OP ([@B42]; [@B56]; [@B11]; [@B16]; [@B36]) and other skeletal disorders ([@B55]; [@B39]). We successfully identified 30 CpG sites in PBMs that may reside along the causal pathway from gene to OP and further ascertained 25 genetic loci that have potential causal effects on the change of DNA methylation at those CpG sites by fine mapping.

Materials and Methods {#s2}
=====================

Human Subjects and Phenotype {#s2_1}
----------------------------

A total of 118 Caucasian women between 20 and 40 years of age were recruited from the subjects participating in our Louisiana Osteoporosis Study, a cross-sectional study with ongoing recruitment to build a large sample pool (\~20,000 subjects) and database for research studies of OP and other musculoskeletal diseases/traits ([@B25]; [@B17]). The 118 subjects included 64 with relatively high BMD and 54 with relatively low BMD, corresponding to hip BMD Z scores ≥0.8 and ≤−0.8, respectively. Hip BMD was determined as the combined BMD of the femoral neck, trochanter, and intertrochanteric region measured by Hologic Discovery-A DXA (dual energy X-ray absorptiometry) machines (model number: 010-0575, Hologic Inc., Bedford, MA, USA) ([@B35]). The DXA machine was calibrated daily, and the coefficient of variation (CV) value of the DXA measurements at total hip on Hologic Discovery-A was 1.0%. The BMD Z score was defined as the number of standard deviations a subject\'s BMD differed from the mean BMD of their age-, gender-, and ethnicity-matched population. The Z-score was reported directly by the Hologic DXA machine which has incorporated the National Health and Nutrition Examination Survey whole body bone data as reference in the system ([@B31]; [@B20]). For each study subject, weight and height were measured using standard procedures, and lifestyle factors (e.g. exercise, alcohol consumption, smoking, etc.) and medical history were assessed by questionnaires. A set of stringent exclusion criteria ([@B15]) were adopted to minimize potential confounding effects of nongenetic influence (by physiological and pharmacological conditions) on BMD variation and alteration in PBM DNA methylation profile. The detailed characteristics of the study subjects are shown in [**Table 1**](#T1){ref-type="table"}.

###### 

Baseline characteristics of subjects from the low and high BMD group.

  ----------------------------------------------------------------------------------------------
                                 Low BMD group (s.d.)   High BMD group (s.d.)   *p*-value
  ------------------------------ ---------------------- ----------------------- ----------------
  **N**                          54                     64                      

  **Age**                        31.8 (4.80)            31.5 (4.97)             0.76

  **Total Hip BMD *Z*-score**\   0.77 (0.06)            1.11 (0.08)             2.2 × 10^-16^
  **(standardized)**                                                            

  **Body mass index (kg/m2)**    21.72 (2.66)           30.03 (8.80)            3.88 × 10^-10^

  **Smoke (% yes)**              0.33                   0.39                    0.65

  **Alcohol drinking (% yes)**   0.91                   0.85                    0.45
  ----------------------------------------------------------------------------------------------

s.d., standard deviation.

PBM Isolation {#s2_2}
-------------

Sixty milliliters of peripheral blood were collected from each subject by a certificated phlebotomist. The fresh blood samples were immediately processed for PBM isolation. First, peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using density gradient centrifugation with Histopaque-1077 (Sigma-Aldrich, USA). Then, PBMs were isolated from PBMCs using Monocyte Isolation Kit II (Miltenyi Biotec Gmbh, Bergisch Glagbach, Germany) according to the manufacturer\'s protocol. The kit contains a highly optimized antibody mix and blocking reagent to deplete T cells, B cells, and natural killer cells from PBMCs, leaving monocytes untouched and free of surface-bound antibody and beads with minimum disturbance. The purity of PBMs isolated using this method was 86% ± 3%. Genomic DNA was extracted from the freshly isolated PBMs with the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, Inc., Valencia, CA), following the manufacturer\'s protocol and stored at −80°C until further use.

Whole-Genome Sequencing Assay {#s2_3}
-----------------------------

Genomic DNA samples extracted from the whole blood were sequenced to 30x coverage on Illumina HiSeq X-Ten with 150 bp paired-end reads. Data quality check was performed on the Illumina sequencing analysis viewer (SAV). Sequence reads were trimmed using Cutadapt (version 1.11) ([@B47]), aligned to GRCh37 (hg19) using BWA-MEM (version 0.7.12-r1039) ([@B40]), duplicates marked with Picard (version 1.129, <http://picard.sourceforge.net>), and coordinates sorted using Samtools (version 1.3) ([@B41]). SNPs were detected by a dual calling strategy using qSNP ([@B30]) and GATK HaplotypeCaller ([@B50]). Variants were annotated with Ensembl v75 gene feature information. Variants were considered "called" and used in the subsequent analysis if they passed the following filters: a minimum read depth of eight reads in each dataset; at least four reads containing the variant where the variant was identified on both strands and not within the first or last five bases. Variants that did not pass these filters were considered "low evidence".

Epigenome-Wide DNA Methylation Assay and Data Processing {#s2_4}
--------------------------------------------------------

Epigenome-wide DNA methylation profiles were determined by reduced representation bisulfite sequencing (RRBS) according to previously published protocols ([@B52]). Briefly, 100 ng genomic DNA from PBMs were digested overnight with MspI restriction enzyme (Thermo Scientific, USA) and then subjected to library construction using the NEXTflex Bisulfite-Seq Library Prep Kit and NEXTflex Bisulfite-Seq Barcodes (BioO Scientific, USA) with a modification of bead size selection to capture MspI fragments of 40--220 bp size. The resulting libraries were bisulfite converted by the EZ DNA Methylation-Gold kit (Zymo Research Corp, USA) and amplified by 20 cycles of PCR using the NEXTflex Bisulfite-Seq U+PCR Master Mix and NEXTflex Primer Mix (BioO Scientific, USA). The bisulfite conversion rate of the EZ DNA Methylation-Gold Kit is ≥99% according to the manufacturer\'s specifications. Different adaptors were used for multiplexing samples into one lane. Library concentrations and quality were measured by Qubit ds DNA HS Assay kit (Life Technologies, USA) and Agilent Bioanalyzer (Agilent, USA). Purified and quantified libraries were pooled at six samples per lane for sequencing and read by 1 × 50 bp on Illumina HiSeq3000. Data quality check was done on Illumina SAV. De-multiplexing was performed with Illumina Bcl2fastq2 v2.17 program and standard FASTQ files were trimmed with Cutadapt v1.3 ([@B47]). The trimmed reads were mapped to the human reference genome (hg19) and converted to methylation values on the 0--1 scale using Bismark v0.10.0 ([@B38]). Only CpG sites with ≥3-fold coverage in at least 30 subjects in each BMD group were included in the subsequent analysis.

Control for Potential Cell Admixture {#s2_5}
------------------------------------

As is true for most tissues, the PBM contains a mixture of several subtypes of cells ([@B78]). This may cause false positives in association analysis if 1) the methylation pattern of subcell types differs and 2) the relative abundance of cell types is correlated with the outcome variable of interest ([@B28]). We adopted a principal component (PC) analysis approach to alleviating the risk of false positive discoveries ([@B72]; [@B43]; [@B48]). The underlying assumption is that subjects with similar cell type compositions will have more similar multi-locus methylation patterns and these patterns can be captured by the PCs. By including the PCs of methylation data as covariates in the association analysis, the potential effects of cell mixture can be regressed out ([@B72]; [@B43]; [@B48]). Similarly, the PC could also help adjust the batch effect and other unmeasured confounders ([@B60]). To obtain the PCs, the methylation data were first normalized by the inverse quantile transformation of the ranked values, which is a robust approach that can reduce the effect of outliers ([@B79]). Based on the variance explained ([**Figure S1**](#SM2){ref-type="supplementary-material"}, [**Table S1**](#SM1){ref-type="supplementary-material"}), the first PC, explaining 26.95% of the methylation variance, was included as a covariate in the following regression analysis.

Epigenome-Wide Association Analysis {#s2_6}
-----------------------------------

Differential methylation analyses were carried out by using R package *methylKit* ([@B1]) with the following logistic regression model at each CpG site for subject *i = 1*,...,*n*
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where *n* is the total number of subjects, *P~i~* is the proportion of methylated cytosines, *X~i~* denotes the BMD group (= 0 for subjects in the low BMD group and = 1 for subjects in the high BMD group), *β* ~0~ denotes the log odds of the control group, and *β* ~1~ denotes the log odds ratio between the high and low BMD groups. Covariates in the model included age, body mass index, drinking status, smoking status, and 1^st^ PC of methylation. We include the PC for methylation for batch effect and cell-type adjustment. The *p*-values for testing the null hypothesis *H* ~0~: β~1~ ~=~ 0 were adjusted by Bonferroni correction to account for multiple testing problems. We performed simulation analyses to calculate the power of detecting methylation difference using logistic regression at different settings of mean sequencing coverage and probability of methylation in the low BMD group (details see [**Supplementary File Part 1**](#SM1){ref-type="supplementary-material"}).

mQTL Analysis {#s2_7}
-------------

Autosomal analysis was applied to 9,265,832 SNPs with a minor allele frequency \> 0.01, genotype hard call rate \> 0.95, and Hardy--Weinberg *p* \> 1 × 10^−6^. The first PC of SNPs, which explains 46% of the variance ([**Figure S2**](#SM2){ref-type="supplementary-material"}, [**Table S2**](#SM1){ref-type="supplementary-material"}), was included as a covariate in the association analysis to control for ancestry and population stratification ([@B61]). To increase the computation speed, we split the SNP and methylation data by chromosome and performed association analysis for each SNP-DMC pair on the same chromosome to identify both *cis*- and *trans*-mQTLs using R package *matrixEQTL*. The SNP was defined *cis* if the distance between SNP and CpG was \<1 Mb and *trans* otherwise. *p*-values were corrected by the Bonferroni approach using the total number of tests of *cis* and *trans* effects ([**Table S3**](#SM1){ref-type="supplementary-material"}) separately to account for the multiple testing problem. SNPs that have a significant (Bonferroni adjusted *p*-value ≤ 0.05) association with DMCs were defined as mQTLs.

MR Analysis {#s2_8}
-----------

The DMCs were further analyzed by MR to estimate the potential mediation effects of DNA methylation on BMD. Considering the lack of power for detecting association due to the limited sample size (N = 118) of our study cohort, we undertook a two-sample MR (2SMR) approach with estimated effects between genetic variants and BMD from published studies ([@B9]). We used DMCs as the exposure and its associated mQTLs as the instrument variables (IVs). The effects of mQTLs on BMD variation were extracted from the GWAS summary statistics for femoral neck BMD from the GEnetic Factors for OSteoporosis Consortium 2015 data release ([@B81]). The mQTL SNPs were further pruned by linkage disequilibrium (LD) correlation. Only SNPs with low LD (*r* ^2^ \< 0.2) were retained to ensure the independence of IVs. If there was only one remaining SNP, we used the Wald ratio test to assess the causal effect of DNA methylation. If there were two or more remaining SNPs, we used inverse-variance weighted (IVW) regression ([@B8]) along with sensitivity analysis by Egger\'s regression ([@B4]) to assess the causal relationship. We performed the MR analysis iteratively through all the DMCs. The DMCs that achieved FDR corrected significance level in the Wald ratio test or IVW regression were defined as mediator DMCs, i.e. methylation at these CpG sites with mediation effects for genetic influences on BMD. The 2SMR was implemented by R package MR-Base ([@B26]).

We also performed reverse MR analysis to evaluate the potential reverse causation (i.e. BMD causes altered DNA methylation at the CpG site of interest) for the mediator DMCs detected in the MR analysis. Because of the limited power to identify SNPs significantly associated with BMD using our study cohort here, the IVs for this analysis were identified with relevant GWAS for BMD reported on the NHGRI-EBI GWAS catalog ([@B45]).

Fine Mapping {#s2_9}
------------

In 2SMR, a set of SNPs that are significantly associated with methylation at a CpG site was required to estimate the causal effect of the methylation. To distinguish the genetic variants with a high probability of causality among all genetic variant associated with a DMC, we performed fine mapping analysis with PAINTOR software ([@B33]; [@B34]). The major advantage of the PAINTOR algorithm is that it incorporates functional annotation information of the genetic variant with the association and LD information to calculate a posterior probability for each SNP to be causal across a locus. Previous simulations have shown that compared to other fine-mapping approaches, PAINTOR has much higher accuracy to select the causal SNPs with annotation information available ([@B33]). LD matrix of the pairwise correlations between SNPs was calculated with PLINK software using our own sample of 118 Caucasian women. Functional annotation included in the analysis were gene elements form GenCode (eight annotations) and chromatin states of monocytes computed from the 15-state hidden Markov model built by NIH Roadmap Epigenomics Project ([@B67]). The annotation files were downloaded from the PAINTOR website (<https://github.com/gkichaev/PAINTOR_V3.0/wiki/2b.-Overlapping-annotations>). We set the maximum number of causal variants in a locus to be two based on our computational capability. The mQTLs that have the largest posterior probability as computed by the PAINTOR algorithm were defined as causal mQTLs.

Test of Pleiotropy Effect {#s2_10}
-------------------------

The observation of the mediation effect of DNA methylation in the 2SMR analysis does not necessarily mean that both DNA methylation and BMD are affected by the same causal variant identified by fine mapping (pleiotropy effect). It is possible that different SNPs that are in high LD causally affect DNA methylation and BMD, respectively (linkage effect, [**Figure 1B**](#f1){ref-type="fig"}). Hence, for mediator DMCs, we tested the heterogeneity in the *b~xy~* values estimated for multiple SNPs in the *cis*-eQTL region using the heterogeneity in dependent instruments (HEIDI) method to distinguish pleiotropy from linkage with multiple SNPs in *cis*-region. Under the null hypothesis of the HEIDI test which assumes pleiotropy, the estimated effect size of DNA methylation on BMD (*b~xy~*) calculated for any SNPs in LD with the causal variant will be identical. Therefore, testing against the null hypothesis is equivalent to testing whether there is heterogeneity in the *b~xy~* values estimated for the causal variant and all other SNPs in the *cis*-mQTL region. In the HEIDI test, we only included SNPs in moderate LD with the causal *cis*-mQTL (0.05 \< *r* ^2^ \< 0.9) which was inferred by the population in our study. We also removed SNPs in the *cis*-mQTL region with an mQTL *p*-value \> 1.6 × 10^−3^ to avoid weak instrumental bias which was the default setting of the SMR software ([@B85]). *p*-value threshold was adjusted by Bonferroni correction using the total number of identified causal mQTLs.

Functional Annotation for DMC, Mediator DMC, and Causal mQTLs {#s2_11}
-------------------------------------------------------------

To test for functional enrichment of the DMCs, we annotate them to seven regulatory categories, including three general regulatory categories (genic regions, CpG islands, and binding sites of CTCF) and fore cell-type specific regulatory categories of CD14^+^ monocyte (histone marks, DNaseI signal peak, chromatin states from the NIH Roadmap Epigenomics Project ([@B67]), and monocyte differentially expressed enhancers from Fantom5 ([@B44])). We mapped each DMC to the annotation categories and recorded overlap at each DMC as a binary variable. To determine whether enrichment occurred more frequently than by chance, we randomly generated 1,000 sets of CpGs (sample size = number of DMCs) from all the input CpGs for differential methylation analysis. For each epigenetic mark, we then calculated the proportion of overlapping CpGs among the DMCs (observed) and that of 1,000 simulated sets of CpGs (expected). We calculated the fold enrichment as observed/expected proportion values and obtained an empirical p value from the distribution of expected proportion values.

We investigated the biological meaning of the DMCs by analyzing the annotations of the nearby genes. We used the Genomic Regions Enrichment of Annotations Tool (GREAT) v3.0.0 to evaluate whether the nearby genes of DMCs are enriched in any gene and human phenotypes ontology terms. To better understand the functional mechanism of the identified causal mQTLs, we annotated each of them to the genic region of specific genes and the regulatory categories as we did for DMC annotation. We use the VEP tool ([@B51]) for gene annotation and prediction of their functional consequences. In addition, we used the Core Expression Analysis function in the Ingenuity Pathway Analysis software (IPA, QIAGEN Redwood City, [www.qiagen.com/ingenuity](www.qiagen.com/ingenuity)) to identify overrepresented canonical pathways, diseases, or disorders and molecular and cellular functions for the nearest genes of causal mQTLs. The experimentally observed molecules and relationships in the IPA Knowledge Base for mammal (humans, mouse, or rat) were used. *p*-values of the right-tailed Fisher exact test were calculated by IPA to assess the enrichment. We also performed gene pathway enrichment analyses using Metascape ([@B83]), in which the following ontology sources were used: KEGG Pathway, GO Biological Processes, Reactome Gene Sets, Canonical Pathways and CORUM. All genes in the genome were used as the enrichment background. Terms with a *p*-value \< 0.01, a minimum count of 3, and an enrichment factor \> 1.5 (the enrichment factor is the ratio between the observed counts and the counts expected by chance) were collected and grouped into clusters based on their membership similarities. The most statistically significant term within a cluster was chosen to represent the cluster ([@B83]).

Results {#s3}
=======

Differentially Methylated CpG Sites {#s3_1}
-----------------------------------

A total of 17,462,566 CpG sites were measured in 54 subjects in the low BMD group and 64 subjects from the high BMD group, of which 1,267,919 CpG sites that were measured with adequate sequencing coverage (N ≥ 3) in more than 30 subjects in each BMD group were used for differential methylation analysis. The mean sequencing coverage of the tested CpGs was 46.52 (95% CI: 22.95\~62.09) fold. We identified 6,149 DMCs significantly associated with BMD at *Pp* \< 3.94 × × 10^-8^ (Bonferroni correction 0.05/1,267,919), including 2,188 DMCs with an absolute difference in methylation values \> 0.05 and 693 DMC with absolute difference ≥ 0.1 between the low and high BMD groups ([**Table S4**](#SM1){ref-type="supplementary-material"} and [**Figure S3**](#SM2){ref-type="supplementary-material"}). Among the 2,188 DMCs with an absolute difference in methylation values \> 0.05, 1,601 (74%) DMCs had mean sequencing coverage \>10 and 1,161 (53%) had mean coverage \>30 ([**Figure S4**](#SM2){ref-type="supplementary-material"}). We estimated that our sample size has approximately 80% power to detect a 0.05 gross difference (total difference caused by methylation and other covariates) at the mean coverage of 30-fold ([**Figure S5**](#SM2){ref-type="supplementary-material"}). We used relatively moderate thresholds for the sequencing coverage and methylation difference in DMC analyses in order to provide a large set of candidates for the downstream analyses.

The GREAT analysis shows that the nearby genes of DMCs with difference \>0.05 are enriched in association with a bone-related human phenotype term, *elevated alkaline phosphatase of bone origin* ([**Figure 3**](#f3){ref-type="fig"}). To evaluate whether our findings are consistent with previous studies, we checked the overlap of DMCs with the significant signals in three previous EWAS of OP ([@B14]; [@B64]; [@B53]). For each DMC identified by our study, we found the nearest signals identified in previous EWAS and calculated the distance between the DMC and the EWAS signals ([**Tables S5**](#SM1){ref-type="supplementary-material"} and [**S6**](#SM1){ref-type="supplementary-material"}). Twelve DMCs are located within 1,000 bp from the previously identified EWAS signals by Delgado-Calle et al. ([@B14]). The low overlap rate between our results and that of Delgado-Calle\'s study is likely due to the very limited overlap of the tested CpG sites between the two studies, and the difference in the studied sample cohorts. Specifically, although we tested 1,267,919 CpGs measured by RRBS, only 33,345 (2.6%) of the tested CpGs were mapped to within 1,000 bp from the CpGs measured by the Illumina 27K array, which was used in the study by Delgado-Calle et al. In addition, our study was perform in PBMs from women aged between 20 and 40 years, whereas the study by Delgado-Calle et al. studied trabecular bone specimens from women aged 59--85 years, with 26 had osteoarthritis and 27 had OP fractures.

![Functional annotation of DMCs with difference \>0.05. The bars represent the top 20 categories in the human phenotype ontology enriched genes near the DMCs. The length of the bars corresponds to values on the x-axis, which are hypergeometric (uncorrected) *p*-values.](fgene-11-00060-g003){#f3}

Construction of Causal Paths: mQTLs, Mediator DMCs and Causal mQTLs {#s3_2}
-------------------------------------------------------------------

As we were particularly interested in DMCs where the DNA methylation may mediate the genetic risk for OP, we applied 2SMR analysis on the 6,149 DMCs. First, we identified 115,727 significant *cis*-DMC-mQTL pairs with *Pp* \< 1.08 × × 10^-9^ (Bonferroni correction 0.05/46,331,365) and 79,188 significant *trans*-DMC-mQTL pairs with *Pp* \< 1.83 × × 10^-11^ (Bonferroni correction 0.05/2,736,230,941), including 125,409 unique mQTLs and 2,618 unique DMCs.

Next, by using mQTLs as the instrumental variables, DNA methylation at DMCs as potential mediators, and BMD groups as the outcome, we found 30 significant mediator DMCs in the 2SMR analysis ([**Table 2**](#T2){ref-type="table"}), among which 11 mediator DMCs showed a positive relationship between DNA methylation and BMD and 19 showed a negative relationship based on the estimated effect sizes. The minimum absolute differences in methylation values of the mediator DMCs is 1.6% between the high versus low BMD groups, while half of mediator DMCs have methylation difference greater than 5% ([**Table 2**](#T2){ref-type="table"}).

###### 

Results of Mendelian randomization analysis.

  DMC^1^            Method   nSNP   b_MR     se_MR   *p*\_MR    b_Egger   se_Egger   *p*\_Egger   Top SNP       Top SNP bp   SNP Overlapped Gene   *p*\_HEIDI   nSNP_HEIDI   Meth_diff   *p*\_DMC
  ----------------- -------- ------ -------- ------- ---------- --------- ---------- ------------ ------------- ------------ --------------------- ------------ ------------ ----------- -----------
  **1:22571385**    IVW      4      0.022    0.004   2.26E-06   0.085     0.051      0.240        rs10917185    22571385     MIR4418               0.341        14           10.600      3.27E-10
  **2:31719473**    IVW      2      -0.024   0.007   3.36E-02   NA        NA         NA           rs151081363   31720272     SRD5A2                0.335        14           -8.963      5.93E-31
  **4:957285**      IVW      2      0.017    0.005   1.86E-02   NA        NA         NA           rs73211813    975238       DGKQ/SLC26A1          0.543        16           -10.465     4.49E-28
  **6:32222711**    IVW      5      -0.030   0.007   3.22E-03   0.162     0.065      0.088        rs454748      32213210     XXbac-BPG154L12.4     0.517        9            -3.770      9.52E-17
  **7:1062527**     IVW      4      0.016    0.004   2.41E-02   -0.001    0.032      0.981        rs4388364     1033045      C7orf50               0.506        20           -2.774      5.29E-17
  **7:56435427**    IVW      10     0.016    0.003   1.28E-05   -0.019    0.024      0.444        rs3813509     56356143     RP11-700P18.1         0.853        8            -11.186     8.40E-47
  **8:58127658**    IVW      9      -0.025   0.003   9.54E-11   0.003     0.041      0.939        rs11786043    58133174     RP11-513O17.2         0.663        18           5.138       1.30E-31
  **9:71682281**    IVW      4      0.016    0.004   2.89E-03   -0.025    0.066      0.744        rs10116497    71634393     PRKACG                0.360        20           -9.207      6.99E-54
  **9:96362114**    IVW      5      0.017    0.004   3.22E-03   0.003     0.137      0.982        rs7857266     96381765     PHF2                  0.376        20           1.662       2.41E-18
  **10:42739065**   IVW      6      0.016    0.004   3.36E-02   0.099     0.173      0.596        rs2489684     42862079     RP11-313J2.1          0.298        20           -3.140      1.70E-18
  **12:48723325**   IVW      4      -0.017   0.005   2.90E-02   -0.049    0.064      0.519        rs10875744    48498440     SENP1                 0.433        9            12.018      1.45E-100
  **14:75441795**   IVW      3      0.015    0.004   3.28E-02   -0.111    0.730      0.904        rs35446981    75637351     TMED10                0.228        4            -6.827      5.95E-11
  **16:81248716**   IVW      2      -0.019   0.005   4.20E-02   NA        NA         NA           rs12925557    81251149     PKD1L2                NA           NA           -10.155     1.37E-29
  **16:89167395**   IVW      3      0.021    0.006   2.91E-02   0.041     0.049      0.554        rs7188200     89167094     ACSF3                 0.557        13           7.130       6.11E-24
  **17:1944903**    WR       1      -0.056   0.012   2.57E-03   NA        NA         NA           rs76439887    1945201      DPH1                  NA           NA           -2.516      2.22E-10
  **17:1944905**    WR       1      -0.061   0.013   2.57E-03   NA        NA         NA           rs76439887    1945201      DPH1                  NA           NA           -3.052      6.39E-20
  **17:42246289**   IVW      2      -0.042   0.006   1.65E-10   NA        NA         NA           rs2526020     42216588     C17orf53              0.451        5            19.333      2.65E-21
  **17:44060776**   IVW      44     0.013    0.001   5.94E-37   0.017     0.017      0.322        rs79724577    43463493     MAPT                  0.735        5            8.741       2.70E-10
  **17:43894548**   IVW      40     0.011    0.001   2.02E-31   0.016     0.006      0.008        rs62054394    43810608     CRHR1                 0.312        17           7.835       2.75E-08
  **17:43828617**   IVW      41     0.015    0.001   5.59E-35   0.015     0.012      0.203        rs62063779    44054671     ARHGAP27              0.177        20           5.094       1.22E-12
  **17:44337590**   IVW      38     -0.022   0.002   3.65E-30   -0.038    0.014      0.011        17:44359021   44359021     ARL17B                0.175        19           -2.539      2.87E-22
  **17:44337597**   IVW      42     -0.022   0.002   3.75E-34   -0.052    0.017      0.004        17:44359021   44359021     ARL17B                0.192        20           -2.557      4.01E-22
  **17:44337613**   IVW      38     -0.022   0.002   5.54E-30   -0.040    0.013      0.004        17:44359021   44359021     ARL17B                0.175        19           -2.316      7.11E-19
  **17:44337604**   IVW      42     -0.022   0.002   2.91E-36   -0.005    0.022      0.819        17:44366572   44366572     ARL17B                0.192        20           -2.308      4.20E-18
  **17:44337617**   IVW      40     -0.022   0.002   1.65E-33   -0.020    0.016      0.220        17:44572989   44572989     RP11-995C19.2         0.176        19           -2.630      5.94E-21
  **17:44337622**   IVW      42     -0.023   0.002   2.91E-36   -0.013    0.021      0.545        17:44572989   44572989     RP11-995C19.2         0.176        19           -2.637      2.50E-20
  **17:80053590**   IVW      6      0.013    0.003   1.30E-03   0.000     0.021      0.984        rs59251877    80056498     FASN                  0.004        7            8.662       1.50E-23
  **17:80086159**   IVW      7      0.014    0.003   7.07E-04   0.004     0.017      0.831        rs59251877    80056498     FASN                  0.004        8            3.921       5.50E-11
  **21:46677414**   IVW      5      0.013    0.004   4.22E-02   -0.013    0.030      0.688        rs28622522    46676599     LINC00334             0.403        20           -2.369      1.53E-09
  **22:46504167**   IVW      2      -0.026   0.007   1.05E-02   NA        NA         NA           rs12170325    46502870     FLJ27365              0.880        4            -4.806      2.14E-11

^1^Format of DMC, chromosome: position.

nSNP, number of SNPs; b, effect size; se, standard error; p, p-value; bp, base pair position; Meth_diff, difference in mean methylation level between BMD groups (high BMD group minus low BMD group).

NA stands for not applicable. NA occurs because the number of associated SNPs (nSNP) is less than three for the Egger regression statistics and no linkage SNP found to be tested for HEIDI test.

To evaluate the potential reverse causation between BMD and methylation at the 30 DMCs, we also carried out reverse 2SMR analysis by using SNPs associated with BMD as the instrumental variables, BMD as the potential mediators, and DNA methylation at DMCs as the outcome. None of the 30 mediator DMCs showed significant evidence of reverse causality after multiple testing correction ([**Table S7**](#SM1){ref-type="supplementary-material"}). Two DMCs (Chr16:89167395 and Chr2:31719473) reached the nominal significance level (0.05) for both the two-stage least square (2SLS) method with multiple linear regression and 2SLS with logistic regression ([**Table S8**](#SM1){ref-type="supplementary-material"}), which further supports the existence of mediation effect at these CpG sites.

The 30 mediator DMCs were fine mapped to 25 causal mQTLs ([**Table 2**](#T2){ref-type="table"}). None of the causal mQTLs has a HEIDI test *p*-value past the threshold 0.001 (0.05/30) after Bonferroni adjustment, suggesting it is unlikely that the SNPs in LD with these causal mQTLs affect BMD.

Biological Significance of the Causal Paths {#s3_3}
-------------------------------------------

The mediator DMC--causal mQTL pairs were mapped to 25 unique genes (the nearest genes of causal mQTLs), of which eight genes have been associated with bone-related phenotype in previous GWAS studies ([**Table 3**](#T3){ref-type="table"}). Three causal mQTLs are in high LD with BMD-associated SNPs reported in GWAS catalog: rs2526020 (in LD with rs227584, *r* ^2^ = 0.8913), rs62054394 (in LD with rs1864325, *r* ^2^ = 1), rs62063779 (in LD with rs1864325, *r* ^2^ = 1). Four causal mQTLs were shared by more than one mediator DMC (rs76439887, 17:44359021, 17:44572989, and rs59251877), which may point to the location of some harbor genes. By overlapping the causal mQTLs and the mediator CpGs with regulatory categories, we found that 10 out of 25 causal mQTLs and 25 out of 30 mediator DMCs reside within cell type-specific histone mark peaks, enhancers, promoters, promoter flanking regions and CTCF binding sites ([**Tables S9**](#SM1){ref-type="supplementary-material"} and [**S10**](#SM1){ref-type="supplementary-material"}), supporting the regulatory potential of these loci.

###### 

Gene annotation of causal mQTLs.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  DMC               Causal mQTLs   mQTL bp    Causal mQTLs\       Gene Type                Traits                          GwasCatalog\            PMID
                                              Overlapped Gene                                                              Study ID                
  ----------------- -------------- ---------- ------------------- ------------------------ ------------------------------- ----------------------- -------------------
  **1:22571385**    rs10917185     22571385   MIR4418             miRNA                    BMD                             GCST001482              22504420

                                                                                           BMD (total hip)                 GCST006143              29883787

                                                                                           Heel BMD                        GCST006433              30048462

                                                                                           Heel BMD                        GCST006979              30598549

                                                                                           Heel BMD                        GCST007066              30595370

                                                                                           Lumbar spine BMD (integral)     GCST007015              27476799

                                                                                           Lumbar spine BMD (trabecular)   GCST007014              27476799

                                                                                           Total body BMD                  GCST005348              29304378

  **2:31719473**    rs151081363    31720272   SRD5A2              Processed transcript                                                             

  **4:957285**      rs73211813     975238     DGKQ                Protein coding           Heel BMD                        GCST006433              30048462

  **4:957285**      rs73211813     975238     SLC26A1             Protein coding                                                                   

  **6:32222711**    rs454748       32213210   XXbac-BPG154L12.4   Antisense                                                                        

  **7:1062527**     rs4388364      1033045    C7orf50             Protein coding           LDL measurement                 GCST006612              30275531

  **7:56435427**    rs3813509      56356143   RP11-700P18.1       Pseudogene                                                                       

  **8:58127658**    rs11786043     58133174   RP11-513O17.2       lincRNA                                                                          

  **9:71682281**    rs10116497     71634393   PRKACG              Protein coding           Blood pressure/cancer           GCST007087/GCST005275   30595370/29299148

  **9:96362114**    rs7857266      96381765   PHF2                Protein coding           Heel BMD                        GCST006288              28869591

                                                                                           Heel BMD                        GCST006433              30048462

                                                                                           Heel BMD                        GCST006979              30598549

                                                                                                                           GCST007066              30595370

  **10:42739065**   rs2489684      42862079   RP11-313J2.1        Pseudogene                                                                       

  **12:48723325**   rs10875744     48498440   SENP1               Protein coding                                                                   

  **14:75441795**   rs35446981     75637351   TMED10              Protein coding           Heel BMD                        GCST006433              30048462

  **16:81248716**   rs12925557     81251149   PKD1L2              Polymorphic pseudogene                                                           

  **16:89167395**   rs7188200      89167094   ACSF3               Protein coding                                                                   

  **17:1944903**    rs76439887     1945201    DPH1                Protein coding                                                                   

  **17:1944905**    rs76439887     1945201    DPH1                Protein coding                                                                   

  **17:42246289**   rs2526020      42216588   C17orf53            Protein coding           BMD                             GCST000297              19079262

                                                                                           BMD                             GCST001482              22504420

  **17:44060776**   rs79724577     43463493   ARHGAP27            Protein coding           Heel BMD                        GCST006433              30048462

  **17:43894548**   rs62054394     43810608   CRHR1               Protein coding           BMD (spine)                     GCST000494              

                                                                                           BMD (hip)                       GCST000495              

                                                                                           Heel BMD                        GCST006433              

                                                                                           Heel BMD                        GCST006979              

                                                                                           Heel BMD                        GCST007066              

  **17:43828617**   rs62063779     44054671   MAPT                Protein coding           BMD                             GCST001482              22504420

                                                                                           Heel BMD                        GCST006433              30048462

  **17:44337590**   17:44359021    44359021   ARL17B              Protein coding                                                                   

  **17:44337597**   17:44359021    44359021   ARL17B              Protein coding                                                                   

  **17:44337613**   17:44359021    44359021   ARL17B              Protein coding                                                                   

  **17:44337604**   17:44366572    44366572   ARL17B              Protein coding                                                                   

  **17:44337617**   17:44572989    44572989   RP11-995C19.2       Pseudogene                                                                       

  **17:44337622**   17:44572989    44572989   RP11-995C19.2       Pseudogene                                                                       

  **17:80053590**   rs59251877     80056498   FASN                Protein coding                                                                   

  **17:80086159**   rs59251877     80056498   FASN                Protein coding                                                                   

  **21:46677414**   rs28622522     46676599   LINC00334           lincRNA                                                                          

  **22:46504167**   rs12170325     46502870   FLJ27365            Protein coding                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

bp, base pair position.

Using IPA software, we identified the top canonical pathways related to the causal mQTLs, shown in [**Table 4**](#T4){ref-type="table"}. In our result, we didn\'t find the most well-known signaling pathways related to bone metabolism, like the Wnt and BMPs (bone morphogenetic proteins) ([@B70]). However, it has been established that OP and cardiovascular disease are functionally interwoven and share some common risk factors like hyperlipidemia ([@B58]). The identification of 'Fatty Acid Biosynthesis Initiation II' in the top canonical pathways, 'Lipid Metabolism' in the top molecular and cellular functions and 'Cardiovascular disease' in the top diseases and disorders ([**Table 4**](#T4){ref-type="table"}) may indicate that lipid metabolism has more important effects on BMD than previously understood. We also performed gene pathway enrichment analysis using Metascape ([@B83]). A GO biological process term related to lipid metabolism (steroid biosynthetic process) showed significant enrichment (*p*-value = 1.45 × × 10^-4^) in genes mapped to causal mQTLs which further supported our findings by IPA ([**Figure S6**](#SM2){ref-type="supplementary-material"} and [**Table S13**](#SM2){ref-type="supplementary-material"}). Finally, we provided a network graph for the genes near the identified causal mQTLs ([**Figure 4**](#f4){ref-type="fig"}), which elucidates the interaction between the identified genes in more detail and may facilitate researchers to discover new drug targets or disease mechanisms.

###### 

Canonical pathways, diseases, and molecular and cellular functions significantly enriched in genes mapped to causal mQTLs.

  Top Canonical Pathways                   *p*-value^1^              Overlap^2^
  ---------------------------------------- ------------------------- ---------------------
  Amyloid processing                       6.79E-04                  3.9% 2/51
  Palmitate biosynthesis                   1.52E-03                  50.0% 1/2
  Fatty acid biosynthesis initiation II    1.52E-03                  50.0% 1/2
  Gas signaling                            2.94E-03                  1.9% 2/107
  CDK5 signaling                           3.00E-03                  1.9% 2/108
  Diseases and Disorders                   ***p*-value range** ^3^   **\#Molecules** ^4^
  Neurological Disease                     4.90E-02--5.29E-04        5
  Organismal Injury and Abnormalities      4.76E-02--5.29E-04        17
  Cancer                                   4.69E-02--7.60E-04        17
  Cardiovascular Disease                   3.52E-02--7.60E-04        1
  Connective Tissue Disorders              4.76E-02--7.60E-04        5
  Molecular and Cellular Functions         ***p*-value range** ^3^   **\#Molecules** ^4^
  Lipid Metabolism                         4.40E-02--3.16E-04        6
  Small Molecule Biochemistry              4.40E-02--3.16E-04        7
  Nucleic Acid Metabolism                  1.21E-02--3.78E-04        5
  Cell Morphology                          4.76E-02--7.60E-04        5
  Cell-To-Cell Signaling and Interaction   4.39E-02--7.60E-04        3

^1^The Fisher\'s exact test *p*-value indicating the significance of enrichment of the causal mQTL genes in the pathway.

^2^In a given pathway, the overlap is calculated as the number of causal mQTL genes enriched in the pathway divided by the total number of genes in that pathway.

^3^The Fisher\'s exact p-value indicating the range of enrichment in the subcategories of each disease/function.

^4^The number of genes that are associated with each disease/function.

![Two predicted nondirectional interaction map of causal mQTL annotated gene by IPA. **(A)** Top mapped disease or functions: cell-to-cell signaling and interaction, cellular assembly, and organization and cellular function and maintenance. **(B)** Top mapped disease or functions: endocrine system disorders, gastrointestinal disease, hereditary disorder. The shaded nodes are gene identified by our analysis. And others are genes/molecules from the Knowledge Base added to the network to fill or join areas lacking connectivity by IPA. Highly interconnected networks are likely to represent significant biological function. For detailed legend see IPA Legend page: <http://qiagen.force.com/KnowledgeBase/articles/BasicTechnicalQA/Legend>.](fgene-11-00060-g004){#f4}

Discussion {#s4}
==========

In this article, we developed a framework for evaluating the causal effect of DNA methylation on a complex trait. This framework combines the MR method with fine mapping and colocalization so that it can distinguish causal relationship from reverse causality, linkage and horizontal pleiotropy ([**Figure 1**](#f1){ref-type="fig"}). Using this framework, we successfully identified 30 causal pathways from genetic variant to BMD phenotype mediated by DNA methylation. Among the 25 corresponding causal genes that we identified, eight genes (*MIR4418, TMED10, C17orf53, CRHR1, ARHGAP27, MAPT, DGKQ, and PHF2*) have been reported to be associated with BMD in previous GWAS ([**Table 3**](#T3){ref-type="table"}).

The *CRHR1* gene was first reported to be significantly associated with BMD in a large-scale meta-analysis of GWAS in 19,195 adults of Northern European descent ([@B66]), and this association was also replicated in East Asian populations ([@B71]). *CRHR1* encodes a G-protein coupled receptor that binds with the neuropeptides of the corticotropin-releasing hormone family, a major regulator of the hypothalamic-pituitary-adrenal pathway with important effects on bone turnover ([@B62]). We identified six causal CpGs located in a CpG island (chr17:44337401-44337926) near the 5\'UTR region of the *CRHR1* gene, of which five are hypo-methylated in the low BMD group and one is hypermethylated. The hypomethylation in the promoter region of *CRHR1* has the potential role of increasing *CRHR1* expression as was identified in a case-control study of panic disorder ([@B69]). In addition, depression, anxiety, and stress have been found to be negatively correlated with BMD ([@B18]). These findings suggested a potential epigenetic regulatory mechanism between hypomethylation of *CRHR1* promoter and low BMD through the regulation of *CRHR1* gene expression.

*C17orf53* gene was associated with BMD and fracture risk in a large genome-wide meta-analysis study, including 17 GWAS and 32,961 individuals of European and East Asian ancestry ([@B19]). A recent study investigated the molecular and cellular functions of a specific BMD-associated SNP (rs227584) in *C17orf53* gene using osteoblastic cells and demonstrated that the SNP rs227584 may alter substrate‐kinase interaction between protein C17orf53 and NEK2 and subsequently regulate osteoblast growth and activity ([@B84]). Our findings complement the previous results and provide further supporting evidence for the significance of *C17orf53* gene on regulating BMD variation and OP risk.

The analytical framework we developed in this study has several prominent strengths. First, we used multiple IVs in the MR analysis, which can offset the low power problem induced by small sample size ([@B57]) and allow for a causal estimate of greater precision than the estimate from any of the individual variants ([@B59]).

Secondly, using multiple independent IVs made it possible to perform sensitivity analysis to assess the bias of the MR results when the IV assumptions are prone to be violated. Horizontal pleiotropy is one of the major potential violations and occurs when the variant influences other traits outside of the pathway of the exposure of interest and has an impact on the target outcome or when the variant has a direct effect on the target outcome. The assumption of no horizontal pleiotropy in classic MR methods is hard to establish unequivocally. Thus, we performed MR analysis by IVW regression alongside the sensitivity analysis by Egger regression to allow for the potential existence of horizontal pleiotropy. IVW will return an unbiased estimate if the horizontal pleiotropy is balanced, that is, the deviation from the mean estimate is independent of all other effects. In addition, Egger regression further relaxes the assumption to the InSIDE (Instrument Strength Independent of Direct Effect) condition ([@B4]), where the instrument-exposure and pleiotropic effects are uncorrelated. The method returns an unbiased causal effect under the InSIDE condition even if the vertical pleiotropy assumption is violated for all SNPs ([@B26]). We identified mediator DMCs primarily based on the test statistics of IVW regression because the Egger regression has very limited power to detect causal effects compared with IVW regression ([@B4]). The Egger regression *p*-values of some mediator DMCs are large, suggesting that the IVW estimate might be biased. However, the causal effects were also assessed by IVW with fixed effects, IVW with multiplicative random effect (IVW-MRE), weighted median and maximum likelihood method. The estimates from other MR methods were consistent with those from the IVW regression in general ([**Table S11**](#SM1){ref-type="supplementary-material"}). Moreover, both the IVW-MRE and weighted median estimates are robust to the existence of horizontal pleiotropy ([@B5]; [@B6]). Thus, we are confident about the estimated effects and the statistical inference of our results. Further research could be done under our analytical framework substituting IVW regression with the recently published MR-PRESSO method that can test and correct the bias caused by horizontal pleiotropy ([@B75]).

Thirdly, our approach has increased power to detect genetic heritability that could be missing in traditional GWAS. The causal mQTLs annotated to those genes associated with bone-related phenotypes in our analysis do not show genome-wide significance in association with BMD ([**Table S12**](#SM1){ref-type="supplementary-material"}). They were not reported to be associated with BMD as we searched in the GWAS catalog database. This phenomenon can be explained by the biological interaction of genetic and epigenetic modification. As the causal mQTLs can only influence the trait *via* the mediation effect of methylation, the causal effect of mQTLs on BMD might be offset and not observed in GWAS without controlling for the mediation effect of DNA methylation. The 2SMR method alone can only give us inferences about the mediator CpGs, not the causal variants. Our analytical framework further incorporates fine mapping of mQTLs and uncovered heritable genetic variants contributing to BMD that are invisible to conventional GWAS by leverage methylation data.

It should be noted that some of the identified DMCs should be treated with caution because of relatively low sequencing coverage, zero-inflated methylation data, and/or relatively high over-dispersion levels ([**Tables S4**](#SM1){ref-type="supplementary-material"} and [**S14**](#SM2){ref-type="supplementary-material"}). Low sequencing coverage affects both sensitivity and specificity in DMC identification depending on the sample size ([@B86]). In addition, an excessive number of zeros in the data might cause extra variance that is difficult for the logistic regression to handle ([@B73]). Although a few statistical approaches (e.g. the zero-inflated binomial model ([@B24])) haven proposed for handling zero-inflated data, however, these approaches have not yet been systemically evaluated for the analysis of DNA methylation data. A comprehensive simulation study is necessary to benchmark the performance of these approaches in DNA methylation analysis, which might be a future extension for us to track. Over-dispersion is another problem likely to happen fitting the methylation data with logistic regression. It refers to a problem of more variability in the data than assumed by the distribution and usually occurs when the observed data does not come from *iid* (independent and identically distributed) distribution ([@B27]). It is realistic to model the observed RRBS data *y~i~* at a CpG site by binomial distribution with subject-specific parameter *N~i~* and group-specific parameter *p*, where *N~i~* represents the sequencing coverage of the subject *i* and *p* represents the probability of methylation. However, the logistic regression method assumes *N~i~* were the same for all subjects, thus may produce inflated association signals for differential methylation analysis ([@B37]). We estimated the over-dispersion scalar for a DMC as the ratio of the observed over the expected variance of methylation value ([**Tables S4**](#SM1){ref-type="supplementary-material"} and [**S14**](#SM2){ref-type="supplementary-material"}). The level of over-dispersion induced inflation of association in differential methylation analysis has not been systematically investigated and is out of the scope of this study. *MethylKit* updated its user\'s guide very recently and is expected to bring up a function for over-dispersion correction by McCullagh and Nelder\'s approach ([@B49]). This new feature could benefit future studies for differential methylation analysis by logistic regression.

The scope of this analysis is to identify the causal paths that are most likely to have a real biological effect on BMD. The causal effect of genetic variants or mediation effect of CpGs should be validated with functional experiments instead of a purely statistical approach. We hope that the identified causal mQTL and mediation CpGs can help to narrow down and prioritize the gene list for potential follow-up biological studies for further validating whether they truly have any functional or pathological significance.

In summary, we demonstrated the value of integration of MR, fine mapping and colocalization analyses in uncovering the causal mechanisms across multi-omics. This approach allowed us to identify CpGs that have mediation influences on genetic variants as well as the proximal causal SNPs that affect the methylation levels at those CpGs. Our results provided novel insights into the genetic and epigenetic mechanisms underlying OP. The identified causal mQTLs and mediation CpGs warrant further functional studies in cell and animal models.
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